Form 8-K - Current report:
SEC Accession No. 0001193125-25-073904
Filing Date
2025-04-07
Accepted
2025-04-07 06:05:40
Documents
14
Period of Report
2025-04-03
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d901196d8k.htm   iXBRL 8-K 26360
2 EX-3.1 d901196dex31.htm EX-3.1 109295
  Complete submission text file 0001193125-25-073904.txt   289917

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA ntla-20250403.xsd EX-101.SCH 2846
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE ntla-20250403_lab.xml EX-101.LAB 18738
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ntla-20250403_pre.xml EX-101.PRE 11704
16 EXTRACTED XBRL INSTANCE DOCUMENT d901196d8k_htm.xml XML 3837
Mailing Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139
Business Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Filer) CIK: 0001652130 (see all company filings)

EIN.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37766 | Film No.: 25816263
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)